Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenusCHIX:GNSL -2.07%68 EV-to-EBITDA is 13.51 as of Sep. 07, 2026, which is 39% below its 10-year median of 22.12. GuruFocus rates CHIX:GNSL with a GF Score™ of 68/100 and a GF Value™ of £20.67 (Fairly Valued). The stock has 5 warning signs investors should review. Among 399 Biotechnology companies, Genus ranks better than 50.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genus's enterprise value is £1,720.9 Mil.
Genus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £127.4 Mil. Therefore, Genus's EV-to-EBITDA for today is 13.51.
The historical rank and industry rank for Genus's EV-to-EBITDA or its related term are showing as below:
CHIX:GNSl'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.13 Med: 22.12 Max: 58.26
Current: 13.51
During the past 13 years, the highest EV-to-EBITDA of Genus was 58.26. The lowest was 13.13. And the median was 22.12.
CHIX:GNSl's EV-to-EBITDA is ranked better than 50.63% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs CHIX:GNSl: 13.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-07), Genus's stock price is £22.74.
Genus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.710. Therefore, Genus's PE Ratio (TTM) for today is 32.03.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genus's share price for today is £22.74.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.710.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Genus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GNSL vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Genus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genus EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genus's EV-to-EBITDA falls into.
Genus's current Enterprise Value is £1,720.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genus's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £127.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genus (CHIX:GNSL) has a EV-to-EBITDA of 13.51 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genus. This is 39% below median its historical median of 22.12. Over the past decade, Genus' EV-to-EBITDA has ranged from 13.13 to 58.26. According to the industry distribution chart, Genus ranks #197 out of 399 companies in the Biotechnology industry, placing it in the top 49.4%.
Is Genus' EV-to-EBITDA too high?
Genus' current EV-to-EBITDA of 13.51 is 39% below median its 10-year median of 22.12. Over the past 10 years, this metric has ranged from a low of 13.13 to a high of 58.26. The Biotechnology industry median EV-to-EBITDA is 13.70. Genus' value of 13.51 is 1.4% below this industry median. Based on the distribution chart, Genus ranks #197 out of 399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genus has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genus' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genus ranks #197 out of 399 companies for EV-to-EBITDA. This puts Genus in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. Genus' value of 13.51 is 1.4% below this benchmark. Historically, Genus' own EV-to-EBITDA has ranged from 13.13 to 58.26 over the past decade. While the company's 10-year median is 22.12 vs. the industry median of 13.70, Genus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genus's current EV-to-EBITDA of 13.51 is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genus. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genus's current EV-to-EBITDA is 13.51, which is 39% below median its own 10-year median of 22.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Based on GuruFocus' analysis, Genus (CHIX:GNSL) is currently considered Fairly Valued. The stock's GF Value™ is £20.67, compared to a current price of £22.74 — trading 10% above its estimated fair value. The current EV-to-EBITDA is 13.51, which is 39% below median its 10-year median of 22.12 and 1.4% below the Biotechnology industry median of 13.70. Genus' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genus (CHIX:GNSL), the current EV-to-EBITDA is 13.51 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genus (CHIX:GNSL) Overvalued in 2026?
Based on GuruFocus' analysis, Genus stock appears to be overvalued.
The current stock price of £22.74 is trading 10% above its estimated GF Value™ of £20.67.
GuruFocus considers Genus to be Fairly Valued.
Key valuation signals for CHIX:GNSL:
EV-to-EBITDA: 13.51 (39% below median its 10-year median of 22.12)
GF Value™: £20.67 vs. price of £22.74 (10% above fair value)
Industry Position: 1.4% below the Biotechnology median (#197 of 399)
No single metric tells the full story. See the CHIX:GNSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
68GF Score
Get the complete analysis for CHIX:GNSL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GNSL has been successfully added to your 
